ScreenerHero

RLMDRelmada Therapeutics Inc

NAS · US · Healthcare · Biotechnology · relmada.com
4.630USD-4.14%Mkt Cap: 493.88M $P/E: —

Relmada Therapeutics, Inc. operates as a clinical-stage biotechnology company in the United States. The company focuses on the development of NDV-01, a controlled-release intravesical formulation of gemcitabine and docet…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap493.88M $
Enterprise Value-63.46M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-57.39M $
Revenue/Share—
Last Price4.630 USD
Fiscal Year EndDec 2025
MR QuarterDec 2019
Employees17
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS75955J4022
Valuation
P/E (Trailing)—
P/E (Forward)-8.29
PEG—
EV/EBITDA4.58
EV/Revenue—
P/S—
P/B0.46
EPS (TTM)-0.87
EPS (Forward)-0.56
52W Range
0.590055% of range8.000
52W High8.000 USD
52W Low0.5900 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-66.33%
ROA-61.05%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-45.79M $
CapEx (TTM)—
FCF Margin—
FCF Yield-1.57%
Net Debt-116.33M $
Net Debt/EBITDA8.40
Balance Sheet
Debt/Equity0.10
Current Ratio80.21
Quick Ratio79.92
Book Value/Sh10.15 USD
Cash/Share10.22 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay DateSep 30, 2019
Splits
Last Split1:4
Split DateSep 30, 2019
Analyst Consensus
Rating1.2 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)12.67 USD
Upside (mean)+173.6%
Target Range9.000 USD – 19.00 USD
$9.000+173.6% to mean$19.00
# Analysts6
Ownership
Shares Out.106.67M
Float7.72M
Insiders2.85%
Institutions95.24%
Short Interest
Short Ratio8.0d
Short % Float13.50%
Short % Out.12.72%
Shares Short13.56M
Short (prev mo.)10.65M
Technical
SMA 505.762 (-19.7%)
SMA 2005.405 (-14.3%)
Beta—
S&P 52W Chg18.16%
Avg Vol (30d)1.47M
Avg Vol (10d)1.32M
Technical Indicators
RSI (14)34.9
MACD-0.3126
MACD Signal-0.3237
MACD Hist.+0.0111
BB Upper5.668 USD
BB Middle5.032 USD
BB Lower4.396 USD
BB Width25.27%
ATR (14)0.3214 USD
Vol Ratio (20d)0.75x